pm mfvt1
    • Main page
      • About journal
      • Articles. Working with contents
      • Editor-in-chief
      • Editorial Council
      • Editorial Board


      • For authors
      • Standards for formatting information
      • Reviewing
      • Politics editorial board
      • Ethics of journal publications


      • For advertisers
      • Subscription
      • About the Publishing House
      • Contact us
  • Bisphosphonate osteonecroses of jaw: risk factors and treatment strategy  

    Редактор | 2017, Practical medicine 07 (17) Obstetrics. Gynecology | 24 сентября, 2017

    M.M. ALEYEVA1, E.V. URAKOVA2, R.V. LEKSIN1

    1Republic Clinical Hospital of the MH of RT, 138A Orenburgskiy Trakt, Kazan, Russian Federation, 420139

    2Kazan State Medical Academy — Branch Campus of the RMACPE MOH Russia, 36 Butlerov Str., Kazan, Russian Federation, 420012

     Aleyeva M.M. ― stomatologist-therapist, maxillofacial surgeon, tel.: (843) 554-54-25, +7-937-616-79-99, e-mail: [email protected]

    Urakova E.V. ― Cand. Med. Sc., Associate Professor of the Department of Maxillofacial Surgery and Surgical Stomatology, tel.: (843) 231-21-10, +7-917-273-65-01, e-mail: [email protected]

    Leksin R.V. ― Head of the Department of Maxillofacial Surgery, tel.: (843) 231-21-10, +7-987-296-89-57, e-mail: [email protected]

     Bisphosphonate drugs can be used to prevent and treat osteoporosis and to reduce symptoms and complications of metastatic bone disease (oncological diseases, multiple myeloma), as well as in diseases such as Paget’s disease and malignant hypercalcemia. However, they are associated with a rare but serious adverse event: osteonecrosis of the maxillary and mandibular bones. This condition is called bisphosphonate-related osteonecrosis of the jaw or BRONJ. The article presents risk factors for this pathology, its clinical manifestations, criteria for diagnosis and treatment.

    Key words: bisphosphonates, osteonecrosis, maxilla, mandibule, concomitant diseases.

    REFERENCES

    1. Kaprin A.D., Starinskij V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’), 2017, pp. 3-4.
    2. Polyakov K.A., Medvedev Yu.A., Omelchenko A.S. Bisfosfonatnyie osteonekrozyi chelyustey: aspektyi patogeneza i klinicheskie proyavleniya. Head and Neck/Golova i sheya, 2013, Rossiyskoe izdanie №2, pp. 20 – 23
    3. G. Anikin, Toropcova N.V. Bisfosfonaty: chto my znaem o nezhelatel’nyh javlenijah, svjazannyh s ih primeneniem. FARMATEKA dlja praktikujushhih vrachej, 2012, no. 19. pp. 81 – 87.
    4. Victoria R., Alexandra L., Laura CI MacDonald, Tanya W., Martin R.T., Nicole B Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ), B Vogt-Ferrier Editorial Group: Cochrane Oral Health Group Published Online, 2016.
    5. Medvedev Yu., Basin E. Fosfornye nekrozy chelyustej. Vrach, 2012, no. 1, pp. 21-25.
    6. Zaslavskaja N.A. Optimizacija profilaktiki i lechenija bisfosfonatnyh osteonekrozov cheljustej u bol’nyh so zlokachestvennymi novoobrazovanijami. Avtoreferat na soiskanie uchenoj stepeni kandidata medicinskih nauk, 2014. pp. 1-25.
    7. Sciubba J., Epstein J. Oral Complications Of Cancer And Its Management. Bisphosphonate-related osteonecrosis of the jaw, 2010, pp. 151-162.

    Метки: 2017, bisphosphonates, concomitant diseases, E.V. URAKOVА, M.M. ALEYEVA, mandibule, maxilla, osteonecrosis, Practical medicine 08 (17) Innovative technologies in medicine, R.V. LEKSIN

    ‹ Difficulties of management of a pregnant woman with familial hypertriglyceridemia: a clinical case   Obesity and short term functional results after a planned total hip replacement ›
    • rus Версия на русском языке


      usa English version site


      Findloupe

      

    • PARTNERS

      пов  logonew
    «Для
    Practical medicine. Scientific and practical reviewed medical journal
    All rights reserved ©